MX358883B - Aumentar el rendimiento de particulas similares a virus en plantas. - Google Patents

Aumentar el rendimiento de particulas similares a virus en plantas.

Info

Publication number
MX358883B
MX358883B MX2014003776A MX2014003776A MX358883B MX 358883 B MX358883 B MX 358883B MX 2014003776 A MX2014003776 A MX 2014003776A MX 2014003776 A MX2014003776 A MX 2014003776A MX 358883 B MX358883 B MX 358883B
Authority
MX
Mexico
Prior art keywords
plant
nucleic acid
plants
performance
increase
Prior art date
Application number
MX2014003776A
Other languages
English (en)
Spanish (es)
Other versions
MX2014003776A (es
Inventor
Andre D´Aoust Marc-
Couture Manon
Vezina Louis-Philippe
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of MX2014003776A publication Critical patent/MX2014003776A/es
Publication of MX358883B publication Critical patent/MX358883B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2014003776A 2011-09-30 2012-09-28 Aumentar el rendimiento de particulas similares a virus en plantas. MX358883B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541780P 2011-09-30 2011-09-30
PCT/CA2012/050681 WO2013044390A1 (en) 2011-09-30 2012-09-28 Increasing virus-like particle yield in plants

Publications (2)

Publication Number Publication Date
MX2014003776A MX2014003776A (es) 2014-08-21
MX358883B true MX358883B (es) 2018-08-31

Family

ID=47994080

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003776A MX358883B (es) 2011-09-30 2012-09-28 Aumentar el rendimiento de particulas similares a virus en plantas.
MX2018006627A MX2018006627A (es) 2011-09-30 2014-03-28 Aumentar el rendimiento de particulas similares a virus en plantas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018006627A MX2018006627A (es) 2011-09-30 2014-03-28 Aumentar el rendimiento de particulas similares a virus en plantas.

Country Status (27)

Country Link
US (1) US11155581B2 (enExample)
EP (2) EP2760882B1 (enExample)
JP (1) JP6248040B2 (enExample)
KR (1) KR101974017B1 (enExample)
CN (2) CN116218900A (enExample)
AU (1) AU2012315421C1 (enExample)
BR (1) BR112014007474A2 (enExample)
CA (1) CA2850407C (enExample)
DK (1) DK2760882T5 (enExample)
ES (1) ES2951259T3 (enExample)
FI (1) FI2760882T3 (enExample)
HR (1) HRP20230695T1 (enExample)
HU (1) HUE062759T2 (enExample)
IL (1) IL231587B (enExample)
IN (1) IN2014CN03077A (enExample)
MX (2) MX358883B (enExample)
MY (1) MY184072A (enExample)
NZ (1) NZ622731A (enExample)
PH (1) PH12014500640A1 (enExample)
PL (1) PL2760882T3 (enExample)
PT (1) PT2760882T (enExample)
RU (1) RU2682752C2 (enExample)
SG (2) SG11201400712VA (enExample)
SI (1) SI2760882T1 (enExample)
TW (1) TWI700368B (enExample)
WO (1) WO2013044390A1 (enExample)
ZA (1) ZA201403059B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
RU2682752C2 (ru) 2011-09-30 2019-03-21 Медикаго Инк. Повышение выхода вирусоподобных частиц в растениях
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
KR102199018B1 (ko) 2013-03-28 2021-01-07 메디카고 인코포레이티드 식물에서 인플루엔자 바이러스-유사 입자 생산
WO2015103704A1 (en) * 2014-01-10 2015-07-16 Medicago Inc. Cpmv enhancer elements
US10563213B2 (en) 2014-03-27 2020-02-18 Medicago Inc. Modified CPMV enhancer elements
MX2020009495A (es) * 2018-03-14 2020-12-07 Medicago Inc Potenciador de la expresion en plantas.
JP2021528970A (ja) 2018-06-27 2021-10-28 メディカゴ インコーポレイテッド インフルエンザウイルスヘマグルチニン変異体
WO2020181354A1 (en) * 2019-03-14 2020-09-17 Mitsubishi Tanabe Pharma Corporation Endogenous plant expression enhancer
WO2021236908A2 (en) * 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5805417A (en) 1995-10-13 1998-09-08 Hitachi, Ltd. Heat dissipation structure in a portable computer including a heat dissipation block extending from a heat dissipation plate through a first circuit board to a CPU on a second circuit board
US6392121B1 (en) 1998-10-07 2002-05-21 Boyce Thompson Institute For Plant Research Gemini virus vectors for gene expression in plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
RU2164148C1 (ru) * 2000-08-09 2001-03-20 Петров Рэм Викторович Вакцина против вируса гриппа и способ ее получения
KR20060029214A (ko) 2003-05-05 2006-04-05 다우 아그로사이언시즈 엘엘씨 이식 유전자 식물 세포들로부터 유래된 안정한 면역예방적및 치료적 조성물들 및 생산방법
KR20060035596A (ko) * 2003-05-05 2006-04-26 보이스 톰슨 인스터튜트 포 플랜트 리서치 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
CN101166827B (zh) * 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
PT1937301E (pt) 2005-10-18 2015-09-14 Novavax Inc Partículas idênticas a vírus (vlps) da gripe funcionais
US20090169576A1 (en) * 2005-10-26 2009-07-02 Roberto Crea Influenza combinatorial antigen vaccine
SG169996A1 (en) * 2006-02-16 2011-04-29 Us Gov Health & Human Serv Antiviral agents and vaccines against influenza
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20100143393A1 (en) 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
US8519113B2 (en) 2006-05-22 2013-08-27 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
JP2009540801A (ja) * 2006-06-16 2009-11-26 ダウ・アグロサイエンス・エル・エル・シー トリインフルエンザ赤血球凝集素の新規なdna配列、ベクターおよびタンパク質
US8697088B2 (en) 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
PL2155880T3 (pl) 2007-06-15 2017-06-30 Medicago Inc. Modyfikacja wytwarzania glikoproteiny w roślinach
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009076778A1 (en) 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
EA034733B1 (ru) 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
WO2010003235A1 (en) 2008-07-08 2010-01-14 Medicago Inc. Soluble recombinant influenza antigens
DK2318530T3 (en) 2008-07-18 2016-10-03 Medicago Inc Ny epitope to immunization against influenza
WO2010025285A1 (en) 2008-08-27 2010-03-04 Arizona Board Of Regents For And On Behalf Of Arizona State University A dna replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
BRPI1015053A2 (pt) 2009-06-24 2019-07-09 Medicago Inc partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
FR2947875B1 (fr) 2009-07-10 2011-07-08 Raymond A & Cie Dispositif de fixation a elements de fixation multiples dont l'un est flottant
WO2011011390A1 (en) 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
SI3354657T1 (sl) 2009-09-22 2022-05-31 Medicago Inc. Postopek za pripravo iz rastlin izpeljanih beljakovin
WO2011102900A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
AU2011312178B2 (en) 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
PL220281B1 (pl) 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
RU2682752C2 (ru) 2011-09-30 2019-03-21 Медикаго Инк. Повышение выхода вирусоподобных частиц в растениях
US11390878B2 (en) * 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
US9555094B2 (en) 2012-07-23 2017-01-31 The Institute Of Biological Resources Isolated nucleic acid for the production of a vaccine against virus
KR102199018B1 (ko) 2013-03-28 2021-01-07 메디카고 인코포레이티드 식물에서 인플루엔자 바이러스-유사 입자 생산

Also Published As

Publication number Publication date
HRP20230695T1 (hr) 2023-12-22
TW201329235A (zh) 2013-07-16
EP2760882A1 (en) 2014-08-06
CA2850407C (en) 2021-11-23
DK2760882T3 (da) 2023-07-03
RU2682752C2 (ru) 2019-03-21
TWI700368B (zh) 2020-08-01
SG10201708052XA (en) 2017-11-29
CA2850407A1 (en) 2013-04-04
AU2012315421A1 (en) 2014-04-10
ZA201403059B (en) 2019-07-31
NZ622731A (en) 2016-04-29
JP2014530006A (ja) 2014-11-17
ES2951259T3 (es) 2023-10-19
FI2760882T3 (fi) 2023-07-17
PT2760882T (pt) 2023-08-07
IL231587B (en) 2020-06-30
JP6248040B2 (ja) 2017-12-13
SI2760882T1 (sl) 2023-10-30
CN103930435A (zh) 2014-07-16
MY184072A (en) 2021-03-17
MX2014003776A (es) 2014-08-21
RU2014116371A (ru) 2015-11-10
SG11201400712VA (en) 2014-04-28
EP2760882B1 (en) 2023-05-24
PH12014500640A1 (en) 2014-05-05
EP3626733A1 (en) 2020-03-25
EP3626733B1 (en) 2024-01-24
HK1200179A1 (en) 2015-07-31
DK2760882T5 (da) 2024-06-24
BR112014007474A2 (pt) 2017-04-04
US20150104480A1 (en) 2015-04-16
IN2014CN03077A (enExample) 2015-07-03
PL2760882T3 (pl) 2023-09-11
IL231587A0 (en) 2014-05-28
AU2012315421C1 (en) 2019-12-05
EP2760882A4 (en) 2015-06-10
KR101974017B1 (ko) 2019-04-30
US11155581B2 (en) 2021-10-26
HUE062759T2 (hu) 2023-12-28
AU2012315421B2 (en) 2017-10-19
WO2013044390A1 (en) 2013-04-04
KR20140068260A (ko) 2014-06-05
CN116218900A (zh) 2023-06-06
MX2018006627A (es) 2020-11-12

Similar Documents

Publication Publication Date Title
MX2018006627A (es) Aumentar el rendimiento de particulas similares a virus en plantas.
MX346905B (es) Produccion de particulas similares a virus en plantas.
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
BR112014012162A2 (pt) partícula similar a vírus, construto de ácidos nucleicos, vetor, célula hospedeira, vegetal ou tecido vegetal, semente ou progênie do vegetal ou tecido vegetal, composição, métodos para isolar e purificar molécula carregada alvo e para proteger molécula alvo contra hidrólise e processo para purificar partículas similares e vírus
EA201000195A1 (ru) Вирусоподобные частицы вируса гриппа, включающие гемагглютинин, продуцированный в растении
PH12015502217A1 (en) Influenza virus-like particle production in plants
PH12013502600A1 (en) Rabies virus like particle production in plants
EA201001198A1 (ru) Рекомбинантные вирусоподобные частицы (вч), схожие с вирусом гриппа, производящиеся в трансгенных растениях, экспрессирующих гемагглютинин
PH12018501452A1 (en) Rotavirus-like particle production in plants
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
BR112015029559A2 (pt) partícula similar a vírus, ácido nucleico e métodos para produzir rna de fita dupla e sirna, shrna, sshrna, 1shrna e mirna
WO2024191860A3 (en) Nucleic acid influenza vaccines and respiratory virus combination vaccines
PH12020552252A1 (en) Influenza virus hemagglutinin mutants
MX387420B (es) Producción de virus en cultivos celulares.
CU20150019A7 (es) Rotavirus humanos modificados
PL406631A1 (pl) Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie
MX364778B (es) Produccion de particulas similares a picornavirus en plantas.
TH171332A (th) การผลิตอนุภาคคล้ายไวรัสโรคพิษสุนัขบ้าในพืช
TH1401001699A (th) การเพิ่มผลผลิตอนุภาคคล้ายไวรัสในพืช
PE20212213A1 (es) Cepas de vbi y usos de las mismas
TN2010000332A1 (en) Recombinant influenza virus-like particles (vlps)produced in transgenic plants expressing hemagglutinin

Legal Events

Date Code Title Description
FG Grant or registration